Bioxyne chief executive Sam Watson has heralded the “remarkable” progress of the company after a strong first quarter saw its share price rally.
The firm reported revenue of A$4.6 million in the three months to September, up 48% on the previous quarter and more than double Q1 FY23.
With quarterly cash receipts of $5.8m, Bioxyne posted a positive operating cash flow of $1.2m.
The encouraging quarter was underscored by deals struck with Montu and Aura Therapeutics to manufacture pastilles at its Brisbane facility.
Continue reading...
